StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV – Get Free Report) in a research note issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.
MediciNova Trading Up 0.7 %
NASDAQ:MNOV opened at $1.39 on Wednesday. MediciNova has a 12 month low of $1.26 and a 12 month high of $2.64. The stock has a 50 day moving average of $1.38 and a two-hundred day moving average of $1.41. The firm has a market cap of $68.18 million, a P/E ratio of -8.18 and a beta of 0.72.
MediciNova (NASDAQ:MNOV – Get Free Report) last posted its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). On average, research analysts forecast that MediciNova will post -0.23 earnings per share for the current year.
Institutional Investors Weigh In On MediciNova
About MediciNova
MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.
Read More
- Five stocks we like better than MediciNova
- Quiet Period Expirations Explained
- Sales Breakout Sends This Semiconductor Stock to Record High
- Stock Market Sectors: What Are They and How Many Are There?
- Surprise Buying Opportunity on This Dividend Aristocrat
- What Are Dividend Contenders? Investing in Dividend Contenders
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for MediciNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova and related companies with MarketBeat.com's FREE daily email newsletter.